<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02217670</url>
  </required_header>
  <id_info>
    <org_study_id>METF-GT016</org_study_id>
    <nct_id>NCT02217670</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability Study of Metformin HCl 1000 mg Granules vs Glucophage 1000 mg Film-coated Tablet</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Disphar International B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Disphar International B.V.</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess comparative bioavailability of a test formulation&#xD;
      of Metformin HCl 1000 mg granules manufactured by Indeus Life Sciences Pvt. Ltd., Mumbai&#xD;
      India (An Affiliate Of Disphar International B.V., The Netherlands) relative to Glucophage&#xD;
      1000 mg film-coated tablets of Merck GmbH, Austria in 54 healthy adult subjects under fed&#xD;
      conditions. The second aim is to asses the safety of subjects and to determine other&#xD;
      pharmacokinetic data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Commercial reasons&#xD;
  </why_stopped>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>Before dosing (0.00 hour) and at the following times after the dose: 0.33, 0.66, 1.00, 1.33, 1.66, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 5.00, 6.00, 8.00, 12.00, 16.00 and 24.00 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Before dosing (0.00 hour) and at the following times after the dose: 0.33, 0.66, 1.00, 1.33, 1.66, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 5.00, 6.00, 8.00, 12.00, 16.00 and 24.00 hours.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>Before dosing (0.00 hour) and at the following times after the dose: 0.33, 0.66, 1.00, 1.33, 1.66, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 5.00, 6.00, 8.00, 12.00, 16.00 and 24.00 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf)</measure>
    <time_frame>Before dosing (0.00 hour) and at the following times after the dose: 0.33, 0.66, 1.00, 1.33, 1.66, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 5.00, 6.00, 8.00, 12.00, 16.00 and 24.00 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCres</measure>
    <time_frame>Before dosing (0.00 hour) and at the following times after the dose: 0.33, 0.66, 1.00, 1.33, 1.66, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 5.00, 6.00, 8.00, 12.00, 16.00 and 24.00 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Before dosing (0.00 hour) and at the following times after the dose: 0.33, 0.66, 1.00, 1.33, 1.66, 2.00, 2.33, 2.66, 3.00, 3.33, 3.66, 4.00, 5.00, 6.00, 8.00, 12.00, 16.00 and 24.00 hours.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events.</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Comparative Bioavailability</condition>
  <arm_group>
    <arm_group_label>Metformin (test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose of Metformin 1000 mg granules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin (reference)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Glucophage 1000 mg film-coated tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 1000 mg granules</intervention_name>
    <arm_group_label>Metformin (test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 1000 mg film-coated tablets</intervention_name>
    <arm_group_label>Metformin (reference)</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 50 years, inclusive.&#xD;
&#xD;
          2. Body Mass Index (BMI) range is within 18.5 - 30.0 Kg/m2.&#xD;
&#xD;
          3. Subject does not have a known allergy to the drug under investigation or any of its&#xD;
             ingredients or any other related drugs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical demographics performed not longer than two weeks before the initiation of the&#xD;
             clinical study with significant deviations from the normal ranges.&#xD;
&#xD;
          2. Results of laboratory tests which are outside the normal range or HbA1c test or liver&#xD;
             or kidney function tests (Creatinine levels and ALP will be accepted if below&#xD;
             reference range) that are outside the reference range or Hb or RBC indices (MCV, MCH,&#xD;
             MCHC) with deviation outside 5% of the reference range.&#xD;
&#xD;
          3. Acute infection within one week preceding first study drug administration.&#xD;
&#xD;
          4. History of drug or alcohol abuse.&#xD;
&#xD;
          5. Subject is a heavy smoker (more than 10 cigarettes per day).&#xD;
&#xD;
          6. Subject does not agree not to take any prescription or non-prescription drugs within&#xD;
             the two weeks preceding the first study drug administration until donating the last&#xD;
             sample of the study.&#xD;
&#xD;
          7. Subject does not agree not to take any vitamins taken for nutritional purposes within&#xD;
             two days before first study drug administration until donating the last sample of the&#xD;
             study.&#xD;
&#xD;
          8. Subject is on a special diet (for example subject is a vegetarian).&#xD;
&#xD;
          9. Subject consumes large quantities of alcohol or beverages containing methylxanthines&#xD;
             e.g. caffeine (coffee, tea, cola, chocolate etc).&#xD;
&#xD;
         10. Subject does not agree not to consume any beverages or food containing alcohol 48&#xD;
             hours prior to study drug administration until donating the last sample in each&#xD;
             respective period.&#xD;
&#xD;
         11. Subject does not agree not to consume any beverages or food containing&#xD;
             methyl-xanthines e.g. caffeine (coffee, tea, cola, chocolate etc.) 24 hours prior to&#xD;
             the study drug administration until the end of confinement period.&#xD;
&#xD;
         12. Subject does not agree not to consume any beverages or food containing grapefruit 7&#xD;
             days prior to first study drug administration until donating the last sample in the&#xD;
             study.&#xD;
&#xD;
         13. Subject has a history of severe diseases which have direct impact on the study.&#xD;
&#xD;
         14. Participation in a bioequivalence/bioavailability study or in a clinical study within&#xD;
             the last 80 days before first study drug administration.&#xD;
&#xD;
         15. Subject intends to be hospitalized within 3 months after first study drugs&#xD;
             administration.&#xD;
&#xD;
         16. Subjects who donated blood or its derivatives in the past 3 months or who through&#xD;
             completion of this study, would have donated more than 1250 ml in 120 days, 1500 ml in&#xD;
             180 days, 2000 ml in 270 days, 2500 ml of blood in 1 year.&#xD;
&#xD;
         17. The female subject is pregnant or lactating.&#xD;
&#xD;
         18. Subject has a history of significant asthma, peptic or gastric ulcer, sinusitis,&#xD;
             pharyngitis, renal disorder (impaired renal function), hepatic disorder (impaired&#xD;
             hepatic function), cardiovascular disorder, neurological disease such as epilepsy,&#xD;
             haematological disorders, type I diabetes or diabetic ketoacidosis, lactic acidiosis,&#xD;
             Vitamin B12 deficiency, psychiatric, dermatologic, immunological disorders or surgery.&#xD;
&#xD;
         19. Subject does not agree not to engage in strenuous exercise at least one day prior to&#xD;
             study drug administration.&#xD;
&#xD;
         20. Subject having at screening examination a pulse outside the normal range of (60-100&#xD;
             beat per minute) or a body temperature outside the normal range of (36.4-37.7 â—‹C) or a&#xD;
             respiratory rate outside the normal range of (14-20 breath per minute) or a sitting&#xD;
             blood pressure less than 100/60 mm Hg or more than or equal to 140/90 mm Hg.&#xD;
&#xD;
         21. Subject has history of difficulties in swallowing or any gastrointestinal disease&#xD;
             which could affect the drug absorption.&#xD;
&#xD;
         22. Subject undergoing radiologic studies involving intravascular administration of&#xD;
             iodinated contrast materials (for example, intravenous urogram, intravenous&#xD;
             cholangiography, angiography, and computed tomography (CT) scans with intravascular&#xD;
             contrast materials).&#xD;
&#xD;
         23. Fasting blood sugar at screening is less than 70 mg/dl.&#xD;
&#xD;
         24. Subject has diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>International Pharmaceutical Research Center</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>August 14, 2014</study_first_submitted>
  <study_first_submitted_qc>August 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

